D. Sommerhalder

Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review

R. Shackelford, P. Peddi, A. Takalkar, 2017, Clinical case reports.

The Use of R-Hyper-CVAD in a Rare Case of Primary Bone Marrow Diffuse Large B-Cell Lymphoma

D. Sommerhalder, Allison Reed, 2019, Journal of hematology.

First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors.

Jennifer L. Caswell-Jin, F. Meric-Bernstam, A. El-Khoueiry, 2022, Journal of Clinical Oncology.

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment

P. Jänne, P. Ascierto, J. Riess, 2023, Molecular Cancer Therapeutics.

652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

K. Arbour, D. Sommerhalder, M. Barve, 2023, Annals of Oncology.